Senate Bill 219 overview
Senate Bill 219, the Medical Psilocybin Act, would create a regulated system to allow patients with qualifying conditions (PTSD, substance use disorders, and end-of-life care) to access and use psilocybin under the guidance of a licensed healthcare provider. New Mexico would join Colorado and Oregon in authorizing facilitated use programs for innovative therapeutic care.
- The program will be managed by the Department of Health (DOH) and a nine-person Medical Psilocybin Advisory Board. Among other duties, the board will oversee the collection and analysis of program results and will include representatives from a tribe, nation, or pueblo and a veteran of the US armed services, among others.DOH will oversee the program, establish training for clinicians and producers, and license producers to grow mushrooms and process psilocybin. DOH will be responsible for determining program aspects such as dosage, administration, production, and storage. DOH will also have authority to expand upon qualifying conditions for treatment.Under SB 219, psilocybin therapy will require at a minimum a preparation session, an administration session and a follow-up integration session, all in DOH-approved settings.
- SB 219 would retain current prohibitions on the commercial manufacture and sale of other psychedelic compounds, and prohibits synthetic psilocybin, as well as driving intoxicated.
Full backgrounder: New Mexico Senate Bill 219 would regulate medical psilocybin access